Palm oil–derived natural vitamin e α-tocotrienol in brain health and disease

Journal of the American College of Nutrition

Volumn 29, Issue , 2010, Pages 314S-323S

  Sen, Chandan K ^a   Rink, Cameron ^a   Khanna, Savita ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Neurodegeneration; Palm oil; Tocotrienol; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ARACHIDONIC ACID; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; PALM OIL; VEGETABLE OIL;

ANIMAL; ARECACEAE; BRAIN; CHEMISTRY; DEGENERATIVE DISEASE; DRUG EFFECT; HUMAN; LIPID PEROXIDATION; METABOLISM; PHYTOTHERAPY; REVIEW;

ANIMALS; ANTIOXIDANTS; ARACHIDONIC ACID; ARECACEAE; BRAIN; HUMANS; LIPID PEROXIDATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PHYTOTHERAPY; PLANT OILS; VITAMIN E;

EID: 79952202387     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2010.10719846     Document Type: Article

References (100)

1. Kiple KF, Ornelas KC: “The Cambridge World History of Food.” New York: Cambridge University Press, 2000.
2. Sundram K, Sambanthamurthi R, Tan YA: Palm fruit chemistry and nutrition. Asia Pac J Clin Nutr 12:355–362, 2003.
3. Edem DO: Palm oil: biochemical, physiological, nutritional, hematological, and toxicological aspects: a review. Plant Foods Hum Nutr 57:319–341, 2002.
4. Sarris A, Food and Agriculture Organization of the United Nations: “Medium-Term Prospects for Agricultural Commodities: Projections to the Year 2010. FAO Commodities and Trade Technical Paper, 1.” Rome: Food and Agriculture Organization of the United Nations, 2003.
5. Sundram K, Hayes KC, Siru OH: Dietary palmitic acid results in lower serum cholesterol than does a lauric-myristic acid combination in normolipemic humans. Am J Clin Nutr 59:841–846, 1994.
6. Ayorinde FO, Garvin K, Saecd K: Determination of the fatty acid composition of saponified vegetable oils using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 14:608-615, 2000.
7. Cater NB, Heller HJ, Denke MA: Comparison of the effects of medium-chain triacylglycerols, palm oil, and high oleic acid sunflower oil on plasma triacylglycerol fatty acids and lipid and lipoprotein concentratioas in humans. Am J Clin Nutr 65:41-45, 1997.
8. Choudhury N, Tan L, Truswell AS: Comparison of palmolein and olive oil: effects on plasma lipids and vitamin E in young adults. Am J Clin Nutr 61:1043-1051, 1995.
9. Katan MB, Zock PL, Mensink RP: Dietary oils, serum lipoproteins, and coronary heart disease. Am J Clin Nutr 61:1368S-1373S, 1995.
10. Ladeia AM, Costa-Matos E, Barata-Passos R, Costa Guimaraes A: A palm oil-rich diet may reduce serum lipids in healthy young individuals. Nutrition 24:11-15, 2008.
11. Sen CK, Khanna S, Roy S: TocotrienoLs in health and disease: the other half of the natural vitamin E family. Mol Aspects Med 28:692-728, 2007.
12. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC: Trans fatty acids and cardiovascular disease. N Engl J Med 354:1601-1613, 2006.
13. Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC: Trans fatty acids and coronary heart disease. N Engl J Med 340:1994-1998, 1999.
14. Mozaffarian D, Pischon T, Hankinson SE, Rifai N, Joshipura K, Willett WC, Rimm EB: Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr 79:606-612, 2004.
15. Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC: Trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr 80:1521-1525, 2004.
16. de Roos NM, Bots ML, Katan MB: Replacement of dietary saturated fatty acids by trans fatty acids lowers serum HDL cholesterol and impairs endothelial function in healthy men and women. Arterioscler Thromb Vase Biol 21:1233-1237, 2001.
17. Remig V, Franklin B, Margolis S, Kostas G, Nece T, Street JC: Traas fats in America: a review of their use, consumption, health implications, and regulation. J Am Diet Assoc 110:585-592, 2010.
18. Evans HM, Emerson OH, Emerson GA: The isolation from wheat germ oil of an alcohol, alpha-tocopherol, having the properties of vitamin E. J Biol Chem 113:319-332, 1936.
19. Evans HM: The pioneer history of vitamin E. In “Vitamins and Hormones,” vol 20. Maryland Heights, MO: Elsevier Science and Technology Books, pp 379-387, 1963.
20. Harman D: Aging: a theory based on free radical and radiation chemistry. J Gerontol 11:298-300, 1956.
21. Harman D: Free radical theory of aging: effect of the amount and degree of unsaturation of dietary fat on mortality rate. J Gerontol 26:451-457, 1971.
22. Kayden HJ, Bjornson L: The dynamics of vitamin E transport in the human erythrocyte. Ann NY Acad Sei 203:127-140, 1972.
23. Azizi E, Zaidman JL, Eshchar J, Szeinberg A: A beta lipoproteinemia treated with parenteral and oral vitamins A and E, and with medium chain triglycerides. Acta Paediatr Scand 67:796-801, 1978.
24. Sokol RJ: Vitamin E deficiency and neurologic disease. Annu Rev Nutr 8:351-373, 1988.
25. Horvath G, Wessjohann L, Bigirimana J, Jansen M, Guisez Y, Caubergs R, Horemans N: Differential distribution of tocopherols and tocotrienols in photosynthetic and non-photosynthetic tissues. Phytochemistry 67:1185-1195, 2006.
26. Venkatesh TV, Karunanandaa B, Free DL, Rottnek JM, Baszis SR, Valentin HE: Identification and characterization of an Arabidopsis homogentisate phytyltransferase paralog. Planta 223:1134-1144, 2006.
27. Cahoon EB, Hall SE, Ripp KG, Ganzke TS, Hitz WD, Coughlan SJ: Metabolie redesign of vitamin E biosynthesis in plants for tocotrienol production and increased antioxidant content Nat Biotechnol 21:1082-1087, 2003.
28. Heinonen M, Piironen V: The tocopherol, tocotrienol, and vitamin E content of the average Finnish diet. Int J Vitam Nutr Res 61:27-32, 1991.
29. Jiang Q, Christen S, Shigenaga MK, Ames BN: Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 74:714-722, 2001.
30. Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G, Williamson KS, West M, Wechter WJ, Floyd RA: New perspectives on vitamin E: gamma-tocopherol and carboxyelthyl-hydroxychroman metabolites in biology and medicine. Free Radie Biol Med 36:1-15, 2004.
31. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ: Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 268:11230-11238, 1993.
32. Pearce BC, Parker RA, Deason ME, Qureshi A A, Wright JJ: Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem 35:3595-3606, 1992.
33. Riley P, Al Bakir M, O’Donohue J, Crook M: Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk. Cardiovasc Ther 27:216-220, 2009.
34. Nesaretnam K, Guthrie N, Chambers AF, Carroll KK: Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 30:1139-1143, 1995.
35. Khanna S, Roy S, Slivka A, Craft TK, Chaki S, Rink C, Notestine MA, DeVries AC, Parinandi NL, Sen CK: Neuroprotective properties of the natural vitamin E alpha-tocotrienol. Stroke 36:2258-2264, 2005.
36. Khanna S, Parinandi NL, Kotha SR, Roy S, Rink C, Bibus D, Sen CK: Nanomolar vitamin E alpha-tocotrienol inhibits glutamate-induced activation of phospholipase A2 and causes neuroprotection. J Neurochem 112:1249-1260, 2010.
37. Khanna S, Roy S, Parinandi NL, Maurer M, Sen CK: Characterization of the potent neuroprotective properties of the natural vitamin E alpha-tocotrienol. J Neurochem 98:1474-1486, 2006.
38. Khanna S, Roy S, Park HA, Sen CK: Regulation of c-Src activity in glutamate-induced neurodegeneration. J Biol Chem 282:23482-23490, 2007.
39. Khanna S, Roy S, Ryu H, Bahadduri P, Swaan PW, Ratan RR, Sen CK: Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem 278:43508-43515, 2003.
40. Sen CK, Khanna S, Roy S, Packer L: Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamate-induced pp60(c-Src) kinase activation and death of HT4 neuronal cells. J Biol Chem 275:13049-13055, 2000.
41. Kaempf-Rotzoll DE, Traber MG, Arai H: Vitamin E and transfer proteins. Curr Opin Lipidol 14:249-254, 2003.
42. Hosomi A, Arita M, Sato Y, Kiyose C, Ueda T, Igarashi O, Arai H, Inoue K: Affinity for alpha-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. FEBS Lett 409:105-108, 1997.
43. Sen CK, Khanna S, Rink C, Roy S: Tocotrienols: the emerging face of natural vitamin E. Vitam Horm 76:203-261, 2007.
44. Jishage K, Arita M, Igarashi K, Iwata T, Watanabe M, Ogawa M, Ueda O, Kamada N, Inoue K, Arai H, Suzuki H: Alpha-tocopherol transfer protein is important for the normal development of placental labyrinthine trophoblasts in mice. J Biol Chem 276:1669-1672, 2001.
45. Terasawa Y, Ladha Z, Leonard SW, Morrow JD, Newland D, Sanan D, Packer L, Traber MG, Farese RV Jr: Increased atherosclerosis in hyperlipidémie mice deficient in alpha-tocopherol transfer protein and vitamin E. Proc Natl Acad Sei USA 97:13830-13834, 2000.
46. Khanna S, Patel V, Rink C, Roy S, Sen CK: Delivery of orally supplemented alpha-tocotrienol to vital organs of rats and tocopherol-transport protein deficient mice. Free Radie Biol Med 39:1310-1319, 2005.
47. Patel V, Khanna S, Roy S, Ezziddin O, Sen CK: Natural vitamin E alpha-tocotrienol: retention in vital organs in response to longterm oral supplementation and withdrawal. Free Radie Res 40:763-771, 2006.
48. Khosla P, Patel V, Whinter JM, Khanna S, Rakhkovskaya M, Roy S, Sen CK: Postprandial levels of the natural vitamin E tocotrienol in human circulation. Antioxid Redox Signal 8:1059-1068, 2006.
49. Contreras MA, Greiner RS, Chang MC, Myers CS, Salem N Jr, Rapoport SI: Nutritional deprivation of alpha-linolenic acid decreases but does not abolish turnover and availability of unacylated docosahexaenoic acid and docosahexaenoyl-CoA in rat brain. J Neurochem 75:2392-2400, 2000.
50. Carlson SE, Werkman SH, Peeples JM, Cooke RJ, Tolley EA: Arachidonic acid status correlates with first year growth in preterm infants. Proc Natl Acad Sei U S A 90:1073-1077, 1993.
51. Eichberg J: “Phospholipids in Nervous Tissues.” New York: Wiley, 1985.
52. Jones CR, Arai T, Rapoport SI: Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem Res 22:663-670, 1997.
53. Neuringer M, Connor WE, Lin DS, Barstad L, Luck S: Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sei U S A 83:4021-4025, 1986.
54. Rapoport SI, Chang MC, Spector AA: Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 42:678-685, 2001.
55. Spector AA: Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J Mol Neurosci 16:159-165; discussion 215-221, 2001.
56. Farooqui A A, Horrocks LA, Farooqui T: Modulation of inflammation in brain: a matter of fat. J Neurochem 101:577-599, 2007.
57. Rapoport SI: Arachidonic acid and the brain. J Nutr 138:2515-2520, 2008.
58. Adibhatla RM, Hatcher JF: Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep 41:560-567, 2008.
59. Clemens JA, Stephenson DT, Smalstig EB, Roberts EF, Johnstone EM, Sharp JD, Little SP, Kramer RM: Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat Stroke 27:527-535, 1996.
60. Lauritzen I, Heurteaux C, Lazdunski M: Expression of group II phospholipase A2 in rat brain after severe forebrain ischemia and in endotoxic shock. Brain Res 651:353-356, 1994.
61. Saluja I, Song D, O’Regan MH, Phillis JW: Role of phospholipase A2 in the release of free fatty acids during ischemia-reperfusion in the rat cerebral cortex. Neurosci Lett 233:97-100, 1997.
62. Stephenson D, Rash K, Smalstig B, Roberts E, Johnstone E, Sharp J, Panetta J, Little S, Kramer R, Clemens J: Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia 27:110-128, 1999.
63. Burke JE, Dennis EA: Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 23:49-59, 2009.
64. Adibhatla RM, Hatcher JF, Larsen EC, Chen X, Sun D, Tsao FH: CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke. J Biol Chem 281:6718-6725,2006.
65. Lin TN, Wang Q, Simonyi A, Chen JJ, Cheung WM, He YY, Xu J, Sun AY, Hsu CY, Sun GY: Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J Neurochem 90:637-645, 2004.
66. Anthonsen MW, Solhaug A, Johansen B: Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis factor-alpha- and interleukin-1 beta-induced NF-kappa B activation. J Biol Chem 276:30527-30536, 2001.
67. Burke JE, Dennis EA: Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50:S237-S242,2009.
68. Stephenson DT, Manetta JV, White DL, Chiou XG, Cox L, Gitter B, May PC, Sharp JD, Kramer RM, Clemeas JA: Calcium-sensitive cytosolic phospholipase A2 (cPLA2) is expressed in human brain astrocytes. Brain Res 637:97-105, 1994.
69. Yoshihara Y, Watanabe Y: Translocation of phospholipase A2 from cytosol to membranes in rat brain induced by calcium ions. Biochem Biophys Res Commun 170:484-490, 1990.
70. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ: cPLA2 is phosphorylated and activated by MAP kinase. Cell 72:269-278, 1993.
71. Phillis JW, Horrocks LA, Farooqui AA: Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 52:201-243, 2006.
72. Beal MF, Howell N, Bodis-Wollner I: “Mitochondria and Free Radicals in Neurodegenerative Diseases.” New York: Wiley-Liss, 1997.
73. Adibhatla RM, Hatcher JF, Dempsey RJ: Lipids and lipidomics in brain injury and diseases. AAPS J 8:E314-E321, 2006.
74. Esterbauer H, Schaur RJ, Zöllner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radie Biol Med 11:81-128, 1991.
75. Kehrer JP, Biswal SS: The molecular effects of acrolein. Toxicol Sei 57:6-15, 2000.
76. Kamal-Eldin A, Appclqvist LA: The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 31:671-701, 1996.
77. Serbinova EA, Packer L: Antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Methods Enzymol 234:354-366, 1994.
78. Kamat JP, Devasagayam TP: Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. Neurosci Lett 195:179-182, 1995.
79. Suzuki YJ, Tsuchiya M, Wassail SR, Choo YM, Govil G, Kagan VE, Packer L: Structural and dynamic membrane properties of alpha-tocopherol and alpha-tocotrienol: implication to the molecular mechanism of their antioxidant potency. Biochemistry 32:10692-10699, 1993.
80. Atkinson J, Epand RF, Epand RM: Tocopherols and tocotrienols in membranes: a critical review. Free Radie Biol Med 44:739-764, 2008.
81. Hamberg M, Samuelsson B: Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sei U S A 71:3400-3404, 1974.
82. Aparoy P, Reddy RN, Guruprasad L, Reddy MR, Reddanna P: Homology modeling of 5-lipoxygenase and hints for better inhibitor design. J Comput Aided Mol Des 22:611-619, 2008.
83. Glickman MH, Klinman JP: Lipoxygenase reaction mechanism: demonstration that hydrogen abstraction from substrate precedes dioxygen binding during catalytic turnover. Biochemistry 35:12882-12892, 1996.
84. Katsuki H, Okuda S: Arachidonic acid as a neurotoxic and neunotrophic substance. Prog Neurobiol 46:607-636, 1995.
85. Canals S, Casarejos MJ, de Bernardo S, Rodriguez-Martin E, Mena MA: Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipoxygenase. J Biol Chem 278:21542-21549, 2003.
86. Nazarewicz RR, Zenebe WJ, Parihar A, Parihar MS, Vaccaro M, Rink C, Sen CK, Ghafourifar P: 12(S)-hydroperoxyeicosatetrae-noic acid (12-HETE) increases mitochondrial nitric oxide by increasing intramitochondrial calcium. Arch Biochem Biophys 468:114-120, 2007.
87. Shimizu T, Wolfe LS: Arachidonic acid cascade and signal transduction. J Neurochem 55:1-15, 1990.
88. Rao AM, Hatcher JF, Kindy MS, Dempsey RJ: Arachidonic acid and leukotriene C4: role in transient cerebral ischemia of gerbils. Neurochem Res 24:1225-1232, 1999.
89. Unterberg A, Schmidt W, Wahl M, Baethmann A: Role of leukotrienes as mediator compounds in brain edema. Adv Neurol 52:211-214, 1990.
90. Canetti C, Hu B, Curtis JL, Peters-Golden M: Syk activation is a leukotriene B4-regulated event involved in macrophage phagocytosis of IgG-coated targets but not apoptotic cells. Blood 102:1877-1883, 2003.
91. Coffey MJ, Phare SM, Peters-Golden M: Role of leukotrienes in killing of Mycobacteriiun bovis by neutrophils. Prostaglandins Leukot Essent Fatty Acids 71:185-190, 2004.
92. Flamand N, Mancuso P, Serezani CH, Brock TG: Leukotrienes: mediators that have been typecast as villains. Cell Mol Life Sei 64:2657-2670, 2007.
93. Michelassi F, Landa L, Hill RD, Loweastein E, Watkias WD, Petkau AJ, Zapol WM: Leukotriene D4: a potent coronary artery vasocoastrictor associated with impaired ventricular contraction. Science 217:841-843, 1982.
94. Schellenberg RR, Foster A: Differential activity of leukotrienes upon human pulmonary vein and artery. Prostaglandins 27:475-482, 1984.
95. Dahlen SE, Bjork J, Hedqvist P, Arfors KE, Hammarstrom S, Lindgren JA, Samuelsson B: Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A 78:3887-3891, 1981.
96. Hambrecht GS, Adesuyi SA, Holt S, Ellis EF: Brain 12-HETE formation in different species, brain regions, and in brain microvessels. Neurochem Res 12:1029-1033, 1987.
97. Bendani MK, Palluy O, Cook-Moreau J, Beneytout JL, Rigaud M, Vallat JM: Localization of 12-lipoxygenase mRNA in cultured oligodendrocytes and astrocytes by in situ reverse transcriptase and polymerase chain reaction. Neurosci Lett 189:159-162, 1995.
98. Tan S, Schubert D, Maher P: Oxytosis: a novel form of programmed cell death. Curr Top Med Chem 1:497-506, 2001.
99. Khanna S, Venojarvi M, Roy S, Sen CK: Glutamate-induced c-Src activation in neuronal cells. Methods Enzymol 352:191-198, 2002.
100. Paul R, Zhang ZG, Eliceiri BP, Jiang Q, Boccia AD, Zhang RL, Chopp M, Cheresh DA: Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 7:222-227, 2001.